Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Name:
mdz253.017.pdf
Size:
91.27Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract
Authors
Domchek, SPostel-Vinay, S
Im, SA
Park, YH
Delord, JP
Italiano, A
Alexandre, J
You, B
Bastian, S
Krebs, Matthew G
Wang, D
Waqar, S
Lanasa, M
Angell, HK
Lai, Z
Gresty, C
Opincar, LM
Herbolsheimer, P
Kaufman, B
Affiliation
Basser Center, University of Pennsylvania, Private Practice - Domchek, PhiladelphiaIssue Date
2019
Metadata
Show full item recordCitation
Domchek S, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. 1191O Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Annals of Oncology. 2019;30(Supplement_5):477.Journal
Annals of OncologyDOI
10.1093/annonc/mdz253.017Additional Links
https://dx.doi.org/10.1093/annonc/mdz253.017Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz253.017